The stock of commercial-stage biotech Travere Therapeutics (NASDAQ: TVTX) barreled into the late holiday period in style. On ...
If you are wondering whether Travere Therapeutics is still good value after its big rebound, you are not alone. This stock has quickly moved from recovery story to serious contender on many watchlists ...
As of Wednesday, December 24, Travere Therapeutics, Inc.’s TVTX share price has surged by 17.75%, which has investors questioning if this is right time to sell.
Travere Therapeutics recently reached a new 52-week high after investors reacted to regulatory updates for its rare kidney disease therapy FILSPARI, including the removal of an FDA advisory committee ...
Cantor Fitzgerald notes that Travere Therapeutics (TVTX) is up 15% following the announcement from Dimerix that the FDA, in written feedback, ...
Investor's Business Daily on MSN
Dow Jones futures fall after Christmas; Nvidia's big AI deal
The Dow Jones set a record close and the S&P 500 hit an intraday high heading into the Christmas holiday. Palantir, Tesla, ...
Roche's Japanese unit Chugai Pharma has reached a deal to buy Renalys Pharma, a company set up to bring therapies developed elsewhere to markets in Asia. Chugai is paying JP 15 billion ($98 million) ...
Otsuka and Vera Therapeutics have both presented new data on drug candidates for IgA nephropathy (IgAN), striving to join a market which is becoming increasingly crowded. Vera Therapeutics reported ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results